BPC-157 Stability, Handling and Catalogue Nomenclature: A Research Review of the Stable Gastric Pentadecapeptide's Sequence Chemistry, Storage Literature and the Notation Family Behind bcp157, bp157 and gpc 157 Labels

By the Peptide Insider Research Desk · 12 min read · Last updated: September 14, 2026

BPC-157 is a synthetic 15-residue fragment (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) of a gastric juice protein termed "body protection compound", first described by the Zagreb group as an anti-ulcer pentadecapeptide that remains intact in human gastric juice for more than 24 hours [1,2]. That unusual stability is the reason the compound is formally called the stable gastric pentadecapeptide, and it is also the reason handling and storage questions dominate research forums. The same peptide circulates in supplier catalogues and search logs under a dense family of labels — bcp157, bp157, bc157, bc 157, gpc 157 peptide, peptides bpc 157, bpc157 peptides and others — most of which are keyboard transpositions or phonetic errors rather than distinct compounds. This review examines the sequence chemistry that underlies the reported stability, what the peer-reviewed literature does and does not say about storage of the lyophilised peptide, and how the catalogue notation family maps back to a single molecule. All content is provided strictly for research reference.

Introduction

BPC-157 has no identified dedicated receptor, and the most-repeated experimental fact about it is physicochemical — that a 15-residue peptide survives in gastric juice, a medium that degrades most peptides within minutes [1]. Our single-compound BPC-157 review covers the tissue-repair literature, and our BPC-157 / TB-500 blend review covers the two-component preparation; neither addresses stability chemistry or the notation problem in depth. This companion article does both; the two topics are connected, because a researcher searching for "bcp157" is usually identifying the same lyophilised vial another researcher is asking whether to refrigerate.

Biological background

The parent protein was isolated from human gastric juice in the early 1990s, and the pentadecapeptide fragment was reported in 1993–1995 under the working name BPC-15 (later BPC 157) as an agent that reduced experimentally induced gastric and colonic lesions in rats [1,2]. Veljaca and colleagues reported in 1995 that intraperitoneally administered BPC-15 reduced trinitrobenzene-sulfonic-acid-induced colonic necrosis and tissue myeloperoxidase activity in a concentration-dependent manner, one of the earliest controlled reports on the peptide [2]. Over the following two decades the Zagreb group and independent laboratories extended the model set to tendon, ligament, skeletal muscle, vascular occlusion and central nervous system injury, summarised in reviews by Sikiric (2011), Gwyer, Wragg and Wilson (2019) and Staresinic and colleagues (2022) [1,6,7]. Gwyer's independent review is notably cautious: most data derive from small rodent models, few groups have studied the compound, and efficacy in humans remains unconfirmed [6].

Structure, sequence chemistry and reported stability

The sequence GEPPPGKPADDAGLV has several features that a peptide chemist would flag when predicting shelf stability, which help explain the "stable" epithet without overstating it.

• No oxidation-prone residues. The sequence contains no cysteine, methionine, tryptophan or histidine, so the oxidative degradation routes that dominate stability profiles of many peptides are absent. This is a structural inference from the sequence, not a measured result.
• A proline-rich N-terminal segment. The Pro-Pro-Pro-Gly-Lys-Pro motif is resistant to many endopeptidases because proline restricts backbone conformation at the cleavage site, a general property of proline-rich sequences that is consistent with the reported persistence in gastric juice [1].
• Two aspartyl residues. The Ala-Asp-Asp-Ala-Gly segment contains aspartic acid residues, which in peptides are candidate sites for succinimide-mediated isomerisation to isoaspartate; Geiger and Clarke showed that rates depend strongly on the residue following Asp, with Asp-Gly fastest and Asp-Ala considerably slower [9]. Whether this occurs measurably in stored BPC-157 has not, to our knowledge, been published.
• An N-terminal glycine and glutamate. N-terminal Glu can cyclise to pyroglutamate under some conditions; the rate for Glu is much lower than for Gln and this route is generally minor [8].

The pharmacokinetic study most often cited for the peptide, He and colleagues (2022), found that after intravenous or intramuscular administration in rats and beagle dogs the intact peptide was eliminated with a half-life under 30 minutes and was metabolised to small fragments and ultimately to free amino acids [3]. Stability in gastric juice therefore does not mean stability in plasma, and catalogue descriptions that conflate the two are not supported by the literature.

Storage and handling: what the literature does and does not say

We identified no peer-reviewed forced-degradation or real-time stability study of lyophilised BPC-157 under defined temperature and humidity conditions. Statements about storage therefore rest on general peptide-formulation science rather than compound-specific data. Manning and colleagues' review of protein and peptide stability sets out the relevant principles [8]:

• Dried solids are more stable than solutions. Chemical degradation pathways (hydrolysis, deamidation, isomerisation, oxidation) require molecular mobility and, in most cases, water; lyophilised solids at low temperature slow them markedly [8].
• Solutions degrade faster and are pH-sensitive. Once a peptide is dissolved, aspartyl isomerisation and hydrolysis proceed at rates set by pH, temperature and buffer composition [8,9].
• Freeze–thaw cycling and light are additional stressors for solutions, and moisture ingress is the principal risk for solids [8].

The question "does bpc 157 need to be refrigerated" is therefore answerable only in general terms: refrigerated or frozen storage of the sealed lyophilised solid is standard laboratory practice for research peptides because it slows the pathways above, but no BPC-157-specific stability claim (for example a defined shelf life at a given temperature) can be cited from the peer-reviewed literature. This article does not provide reconstitution or handling protocols; those are laboratory SOP matters outside its scope.

Nomenclature and catalogue variants

Because BPC-157 was never assigned a widely used international nonproprietary name, catalogues and search engines carry a wide notation family. The table groups the strings encountered most often, with our interpretation of each. Every row denotes the same 15-residue sequence unless stated otherwise.

Catalogue / search string	Notation type	Interpretation
BPC-157, BPC 157, BPC157	Canonical (hyphen / space / concatenated)	Standard designation used in the peer-reviewed literature [1]
PL 14736, PL-10, BPC-15	Historical / development codes	Earlier designations used by the originating group in 1990s papers [1,2]
bcp157, bcp157 peptide, peptide bcp157	Letter transposition (C↔P)	The most common misspelling; "BCP" is a keyboard transposition of "BPC", not a different compound
bp157, bp157 peptides	Dropped letter	"BP" omits the C; denotes BPC-157 in every listing we examined
bc157, bc 157	Dropped letter (P)	Same sequence; not to be confused with unrelated "BC" catalogue prefixes
bbc157 peptides	Doubled letter	Typing error for BPC-157
gpc 157 peptide	Phonetic / adjacent-key error (G for B)	Misspelling of BPC-157; "GPC" otherwise denotes glycerophosphocholine, an unrelated small molecule
peptides bpc 157, peptides bpc-157, bpc157 peptides	Word-order / plural variants	Search-engine phrasings for the same compound; the plural does not indicate a family
bpc-157 5mg	Vial-content attribute	Catalogue label describing lyophilised content per vial; a catalogue attribute, not a protocol
bpc tb 500, bpc tb500 blend	Two-compound blend label	BPC-157 co-formulated with TB-500 (thymosin β4 fragment); see the blend review
klow peptide blend bpc-157 tb-500 ghk-cu 80 mg	Multi-compound blend label with total content	Four-component "KLOW" catalogue preparation; see the KLOW review

Vanhee and colleagues' analysis of peptide products seized by European control agencies is a useful reminder of why notation matters: label text is not evidence of identity, and LC-MS/MS confirmation of sequence and mass is the only reliable way to establish what a vial contains [10]. A listing spelled "bcp157" and one spelled "BPC-157" may be identical or may differ materially; the certificate of analysis, not the spelling, settles the question.

Evidence by domain

Domain	Model system	Reported observation	Key refs
Gastrointestinal lesions	Rat (TNBS colitis, NSAID and alcohol lesion models)	Reduced lesion area and myeloperoxidase activity; peptide stable in gastric juice	[1,2]
Tendon and ligament	Rat Achilles fibroblasts; transection models	Increased fibroblast outgrowth, migration and survival under oxidative stress via FAK–paxillin phosphorylation	[4,6]
Angiogenesis and vascular	CAM assay, HUVEC tube formation, rat hind-limb ischaemia	Increased vessel density; VEGFR2 up-regulation and internalisation with Akt–eNOS activation, without increased VEGF-A	[5]
Skeletal, smooth and cardiac muscle	Rat injury and toxicity models	Improved functional recovery in muscle transection, crush and disturbance models	[7]
Pharmacokinetics	Rat and beagle dog	Linear kinetics; elimination half-life under 30 min; metabolism to amino acids; urinary and biliary excretion	[3]

Gastrointestinal models

The original programme reported protective effects across esophageal, gastric, duodenal and colonic lesion models in rats and in fistula and anastomosis models, and Sikiric's 2011 review collates these with proposed interactions with the nitric-oxide, dopamine and prostaglandin systems [1]. The 1995 TNBS colitis study reported reductions in both macroscopic necrosis and the neutrophil marker myeloperoxidase [2].

Tendon fibroblast biology

Chang and colleagues (2011) found that BPC-157 accelerated outgrowth of rat Achilles tendon fibroblasts from explants, improved survival under hydrogen-peroxide stress, and increased migration and spreading with F-actin formation, without changing proliferation rate; Western blotting showed increased phosphorylation of focal adhesion kinase and paxillin [4]. Gwyer's review places this among transection models while stressing that human translation is unproven [6].

Angiogenesis

Hsieh and colleagues (2017) reported that BPC-157 increased vessel density in chick chorioallantoic membrane and endothelial tube-formation assays and accelerated blood-flow recovery in rat hind-limb ischaemia, associated with up-regulation and internalisation of VEGFR2 and activation of the Akt–eNOS cascade; the endocytosis inhibitor dynasore blocked these effects [5].

Limitations of the evidence base

• Concentration of authorship. A large share of publications originate from a single research group; independent replication, while present for tendon and angiogenesis mechanisms, is limited [6].
• No receptor. Effects are described through downstream markers (FAK, VEGFR2, NO) without an identified binding target, which complicates mechanistic interpretation [4,5].
• Species and scale. Almost all in vivo data are from rats; the 2022 pharmacokinetic study in dogs is the largest-species dataset located [3,6].
• No compound-specific stability data. As noted above, storage statements rest on general peptide chemistry, not BPC-157 measurements [8,9].
• Regulatory status. The compound is not approved for human therapeutic use anywhere and is listed under WADA Section S0 [11]. Vanhee's work shows that products sold under such names are frequently misidentified or mis-quantified [10].

Where to source for research

BPC-157 is listed by several research-chemical suppliers as a lyophilised powder in vials described by milligram content, and, given the notation family documented above, it is frequently listed under misspelled labels. Researchers evaluating a supplier should request a lot-specific certificate of analysis with HPLC purity and mass-spectrometric confirmation of the 1,419 g/mol pentadecapeptide, regardless of how the product name is spelled. Current research-grade availability includes Short Chain Aminos, BioPep, Catalyst Research and Apex Research Services. Our supplier evaluation guide and supplier reviews outline the documentation researchers can reasonably expect. All listings are for laboratory research use only.

Frequently asked questions

What is bpc-157 peptide?

BPC-157 is a synthetic 15-amino-acid fragment (GEPPPGKPADDAGLV, about 1,419 g/mol) of a protein found in human gastric juice. It has been studied in rodent models of gastrointestinal, tendon, ligament, muscle and vascular injury and is notable for remaining intact in gastric juice for over 24 hours. It is a research compound, not an approved medicine [1,6].

Are bcp157, bp157 and bc157 different from BPC-157?

No. "bcp157" is a C↔P letter transposition, "bp157" and "bc157" drop one letter, and "bbc157" doubles one. All denote the same pentadecapeptide. Because label spelling is not evidence of identity, researchers should confirm sequence and mass on the certificate of analysis rather than relying on the product name [10].

Is gpc 157 peptide the same compound?

"gpc 157 peptide" is a misspelling of BPC-157 (G is adjacent to B on many keyboards). It should not be confused with GPC, the common abbreviation for glycerophosphocholine, which is a choline-containing small molecule unrelated to any peptide. Listings using "gpc 157" describe BPC-157 [1].

Does bpc 157 need to be refrigerated?

No peer-reviewed stability study of lyophilised BPC-157 exists, so no compound-specific shelf-life claim can be cited. General peptide-formulation science indicates that dried solids at low temperature degrade far more slowly than solutions, which is why refrigerated or frozen storage of sealed lyophilised research peptides is standard laboratory practice. Handling protocols are outside the scope of this review [8,9].

Why is BPC-157 called "stable"?

The epithet refers to its reported persistence in human gastric juice for more than 24 hours, unusual for a short peptide and consistent with its proline-rich sequence and absence of oxidation-prone residues [1]. It does not mean the peptide is stable in plasma: in rats and dogs the intact peptide had an elimination half-life under 30 minutes [3].

What does "bpc tb 500" or "bpc tb500 blend" mean?

These are catalogue labels for a two-component lyophilised preparation combining BPC-157 with TB-500, a synthetic fragment of thymosin β4. No peer-reviewed study of the combined preparation has been published; the evidence bases are separate. Research catalogue listings frequently pair BPC-157 and TB-500. Our blend review examines the pairing in detail [1,6].

Is BPC-157 approved or permitted in sport?

BPC-157 is not approved for human therapeutic use by any regulatory authority. In 2022 WADA named it explicitly under Section S0 (Non-approved Substances) of the Prohibited List, meaning it is prohibited at all times in WADA-compliant sport [11].

Works Cited

1. Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Curr Pharm Des. 2011;17(16):1612–1632. doi:10.2174/138161211796196954. PMID 21548867.
2. Veljaca M, Lesch CA, Pllana R, Sanchez B, Chan K, Guglietta A. BPC-15 reduces trinitrobenzene sulfonic acid-induced colonic damage in rats. J Pharmacol Exp Ther. 1995;272(1):417–422. PMID 7815358.
3. He L, Feng D, Guo H, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Front Pharmacol. 2022;13:1026182. doi:10.3389/fphar.2022.1026182. PMC9794587.
4. Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011;110(3):774–780. doi:10.1152/japplphysiol.00945.2010. PMID 21030672.
5. Hsieh MJ, Liu HT, Wang CN, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95(3):323–333. doi:10.1007/s00109-016-1488-y. PMID 27847966.
6. Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. 2019;377(2):153–159. doi:10.1007/s00441-019-03016-8. PMID 30915550.
7. Staresinic M, Japjec M, Vranes H, et al. Stable gastric pentadecapeptide BPC 157 and striated, smooth, and heart muscle. Biomedicines. 2022;10(12):3221. doi:10.3390/biomedicines10123221.
8. Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544–575. doi:10.1007/s11095-009-0045-6. PMID 20143256.
9. Geiger T, Clarke S. Deamidation, isoaspartate formation, and racemization at asparaginyl and aspartyl residues in peptides. Succinimide-linked reactions that contribute to protein degradation. J Biol Chem. 1987;262(2):785–794. PMID 3805008.
10. Vanhee C, Janvier S, Desmedt B, et al. Analysis of illegal peptide biopharmaceuticals frequently encountered by controlling agencies. Talanta. 2015;142:1–10. doi:10.1016/j.talanta.2015.04.022. PMID 26003685.
11. World Anti-Doping Agency. WADA's 2022 Prohibited List now in force (Section S0, Non-approved Substances: BPC-157). 2022. wada-ama.org.

All content strictly for research reference. BPC-157 is a research compound in this context; it is not for human or veterinary use, and nothing in this article constitutes guidance on handling, reconstitution, administration or protocols. Related reviews: BPC-157 tissue-repair review · BPC-157 / TB-500 blend · TB-500 and thymosin β4 · KLOW blend.